Source comparison
Using BPC-157 for Joint Pain Research Evidence: Peptide Comparison
BPC-157 VEGF receptor 2 activation, FAK-paxillin pathway modulation Zero published RCTs Accelerated tendon healing (33% timeline reduction), increased fibroblast density (72% vs controls) 200–500 mcg daily (extrapolated from allometric scaling) Strong preclini
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF receptor 2 activation, FAK-paxillin pathway modulation
- Zero published RCTs
- Accelerated tendon healing (33% timeline reduction), increased fibroblast density (72% vs controls)
- 200–500 mcg daily (extrapolated from allometric scaling)
- Strong preclinical signal with complete absence of human validation. Research use requires acknowledging exploratory status
- TB-500 (Thymosin Beta-4)
- Actin sequestration, endothelial cell migration
- Case series only, no controlled trials
- Improved wound healing, enhanced angiogenesis in cardiac injury models
- 2–10 mg loading, 2–5 mg maintenance
- Similar evidence profile to BPC-157. Robust animal data without clinical confirmation
- GHK-Cu (Copper Peptide)
- Collagen synthesis stimulation, MMP modulation
- Small dermatology trials (wound healing), no joint-specific studies
- Enhanced collagen deposition, reduced inflammation in skin wound models
- 1–3 mg topical or subcutaneous
- Mechanism less specific to joint tissue than BPC-157; evidence base similarly limited